Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the pr
- PDF / 179,878 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 41 Downloads / 232 Views
u1 · F. Putz1 · G. Lahmer1 · S. Semrau1 · R. Buslei2 1 Klinik für Strahlentherapie, Erlangen 2 Neuropathologisches Institut des Universitätsklinikums Erlangen und des CCC Erlangen
Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution
Editorial Several studies have addressed the prognostic and predictive value of the methylation status of the O6-methylguanineDNA methyltransferase (MGMT) gene in patients with glioblastoma multiforme (GBM). In a translational study analyzing the randomized EORTC-26981-22981/ NCIC-CE3 trial by Stupp et al. [9], Hegi and coworkers [4] first demonstrated that the benefit of combined radiotherapy and temozolomide chemotherapy over radiotherapy alone was significant in GBM patients with a methylated MGMT promoter (median survival: 21.7 versus 15.3 months; p
Data Loading...
